09/15/2022
LuPSMA: The Specifics (Part 2)
A whole new form of treatment for metastatic castrate-resistant prostate cancer (mCRPC) is here: PSMA-targeting therapy. The first PSMA-targeting therapy approved in the U.S. – with more being tested now in clinical trials – is LuPSMA (177Lu-PSMA-617; Pluvicto®), previously discussed here. We asked medical oncologist and PCF-funded scientist Michael J.. Read More
09/15/2022
LuPSMA: A Whole New Class of Treatment for Prostate Cancer (Part 1)
PSMA is a molecule that sits on the surface of prostate cancer cells, and we can look right at it. It can’t hide from us – even in bits of cancer no bigger than a grain of rice – because, thanks to research funded by PCF, newly-approved radioactive tracers that. Read More
07/26/2022
Researchers Identify a New Subtype of Advanced Prostate Cancer
A PCF-funded study published in the prestigious journal Science has identified a new subtype of castration-resistant prostate cancer (CRPC). Understanding how genes and proteins “drive” this particular type of cancer may lead to new treatments. In the early stages, prostate cancer cells are driven by androgens (e.g., testosterone), which naturally. Read More
06/24/2022
Highlights from the American Society of Clinical Oncology 2022 Annual Meeting, Part 1
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest scientific meetings focused on cancer, where physicians, scientists, advocates, and industry partners share the latest developments in research and treatment. At the 2022 meeting held in Chicago this summer, there were multiple presentations on 177Lutetium-PSMA-617 (Lu-PSMA;. Read More
06/06/2022
Alternative Endpoints: Results that Potentially Accelerate Phase 3 Clinical Trials in Metastatic Hormone-Sensitive Prostate Cancer
Clinical trials can bring life-extending and potentially curative new treatments to patients with cancer. They play a vital role in determining the safety and efficacy of investigational treatments, generating data which the FDA requires for making decisions on whether a new therapy can be approved and enter widespread clinical practice.. Read More
05/18/2022
Metastatic Prostate Cancer: Don’t Accept Complacency!
“This is all we can do” is a phrase no cancer patient wants to hear, especially someone with metastatic disease. Medical oncologist and PCF-funded investigator Andrew Armstrong, M.D., M.Sc., hears those six words a lot – from patients who have come to see him at Duke University’s Cancer Center, a. Read More
05/10/2022
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
If you’ve been diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC), you have many treatment options. Doctors and researchers at the Advanced Prostate Cancer Consensus Conference held in April 2022 in Lugano, Switzerland reviewed the latest clinical trial information and highlighted key points for clinicians. Metastatic prostate cancer means that prostate. Read More
10/03/2016
Questions to Ask your Doctor: Recurrence of Prostate Cancer
When it is caught early, prostate cancer is usually curable. However, some men may see a return of their cancer, which can occur many years later. Generally, this will be noticed because of a rising PSA, and your doctor may recommend more treatment. Here are a few questions to ask. Read More